Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin nasal spray for social dysfunction in pediatric autism spectrum disorder
ChiCTR1800017720Phase 4Recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Oxytocin nasal spray with Placebo (2 arms). Primary endpoint: Social Responsiveness Scale. Started Aug 2018; status: recruiting.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ChiCTR1800017720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017720.